NurExone Biologic Invited to Present Breakthrough ExoPTEN Therapy at Prestigious September Conferences Page 1

Participation in the events in Boston and New York underscores the company’s prominent role in regenerative medicine and exosome technology

TORONTO and HAIFA, Israel, Aug. 23, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExon”) is pleased to announce that its Chief Executive Officer, Dr. Lior Shaltiel, has been invited to speak at the upcoming Bioprocess International Conference, being held September 23-26 in Boston, MA. NurExone’s participation in this event highlights the company’s leadership in the field of exosomes for clinical applications and regenerative medicine. Dr. Shaltiel will present the company’s promising ExoPTEN nanodrug, a potential treatment for acute spinal cord injuries and other central nervous system indications, such as glaucoma care.